Global Immunoprotein Diagnostic Testing Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Immunoprotein Diagnostic Testing Market Size

• The global immunoprotein diagnostic testing market size was valued at USD 9.60 billion in 2024 and is expected to reach USD 16.75 billion by 2032, at a CAGR of 7.20% during the forecast period
• The market growth is largely fueled by the increasing prevalence of chronic and infectious diseases, coupled with rising demand for early and accurate diagnostic solutions. The adoption of immunoprotein diagnostic testing is expanding rapidly across hospitals, diagnostic laboratories, and research institutions
• Furthermore, advancements in immunoassay technologies, automation, and high-throughput testing platforms are enhancing the precision, efficiency, and scalability of immunoprotein diagnostics. These technological improvements are driving broader adoption across clinical and research settings

Immunoprotein Diagnostic Testing Market Analysis

• Immunoprotein diagnostic testing, involving the analysis of immune-related proteins for disease diagnosis and monitoring, is increasingly critical in clinical diagnostics across hospitals, laboratories, and research centers
• The growing demand for immunoprotein diagnostic tests is driven by the rising prevalence of chronic and infectious diseases, technological advancements in assay platforms, and expanding applications in oncology and personalized medicine
• North America dominated the immunoprotein diagnostic testing market with the largest revenue share of 40.5% in 2024, supported by advanced healthcare infrastructure, high disposable incomes, and a strong presence of key industry players. The U.S. specifically experienced significant growth through innovations in immunoassay technologies and expanding diagnostic capabilities across diverse clinical settings
• Asia-Pacific is expected to be the fastest growing region in the immunoprotein diagnostic testing market during the forecast period, fueled by rapid urbanization, increased healthcare access, and rising investments in diagnostic technologies in countries such as China and India
• The enzyme-linked immunosorbent assay (ELISA) segment dominated the immunoprotein diagnostic testing market with a revenue share of 38.9% in 2024, owing to its high sensitivity, specificity, and versatility in detecting a broad range of immunoproteins

Report Scope and Immunoprotein Diagnostic Testing Market Segmentation 

Immunoprotein Diagnostic Testing Market Trends

Growing Demand for Advanced Immunoprotein Diagnostic Solutions

• A significant and accelerating trend in the global immunoprotein diagnostic testing market is the increasing adoption of high-precision diagnostic assays and integrated testing platforms. These advancements are enhancing the accuracy, reliability, and speed of detecting various immunoproteins, which is critical for early disease diagnosis and monitoring
  • For instance, laboratories are increasingly utilizing automated immunoturbidity systems and enzyme-linked immunosorbent assays (ELISA) to efficiently measure protein biomarkers, improving diagnostic throughput and reducing human error
• The adoption of multiplex testing and high-throughput platforms allows clinical laboratories to simultaneously analyze multiple immunoproteins, offering comprehensive diagnostic insights with faster turnaround times
• Integration with digital laboratory management systems is facilitating centralized data handling, seamless reporting, and better decision-making for clinicians. This connectivity ensures that test results are easily accessible, traceable, and compatible with electronic health records (EHRs)
• The trend toward more precise, standardized, and automated immunoprotein testing is reshaping diagnostic workflows, enabling healthcare providers to offer more targeted and personalized patient care
• The demand for advanced, reliable, and scalable immunoprotein diagnostic solutions is growing rapidly across hospitals, diagnostic laboratories, and research centers, driven by the need for early detection, accurate monitoring of diseases, and effective treatment planning

Immunoprotein Diagnostic Testing Market Dynamics

Driver

Growing Need Due to Rising Awareness of Immunoprotein Testing

• The increasing prevalence of chronic and infectious diseases, coupled with rising awareness among healthcare providers and patients about the importance of early and precise diagnostics, is a significant driver for the heightened demand for Immunoprotein Diagnostic Testing
  • For instance, in April 2024, several laboratories expanded their capacity for multiplex immunoprotein assays to improve detection rates of autoimmune and infectious conditions. Such strategic expansions by key companies are expected to drive the Immunoprotein Diagnostic Testing industry growth in the forecast period
• As healthcare providers emphasize personalized medicine and precise monitoring of biomarkers, immunoprotein diagnostic tests are increasingly employed for timely disease identification and effective treatment planning. This enables clinicians to optimize patient outcomes and improve long-term health management
• Furthermore, the growing adoption of integrated laboratory information systems and automated immunoprotein testing platforms is facilitating faster sample processing, reliable results, and seamless integration with hospital and clinic workflows, increasing efficiency and reducing human error
• The convenience of rapid test results, comprehensive biomarker profiling, and compatibility with routine laboratory processes are key factors propelling the adoption of Immunoprotein Diagnostic Testing in hospitals, diagnostic laboratories, and research centers. The trend towards enhanced accessibility and user-friendly diagnostic solutions further contributes to market growth

Restraint/Challenge

High Costs and Technical Expertise Requirements

• The high initial investment required for acquiring advanced immunoprotein testing systems and fully automated diagnostic platforms presents a notable challenge to broader adoption. This is particularly evident in small laboratories, regional healthcare centers, and resource-limited facilities, where budget constraints limit the ability to procure high-end equipment, thereby slowing market penetration
• Furthermore, the complexity associated with certain immunoprotein assays necessitates the presence of highly skilled laboratory personnel and specialized training programs. Ensuring accuracy, reproducibility, and reliability of test results demands rigorous technical expertise, creating operational barriers for some healthcare institutions and limiting the widespread implementation of these tests
• To address these challenges, simplifying testing workflows, providing comprehensive training programs, and developing cost-effective immunoprotein diagnostic kits are crucial strategies. Such measures can help expand market reach by making sophisticated testing solutions more accessible to a broader range of laboratories and healthcare providers
• While the cost of some testing platforms is gradually decreasing due to technological advancements and increased competition, the perceived high expense of advanced immunoprotein assays continues to act as a barrier. This is particularly significant in developing regions and for smaller-scale clinical setups that may lack sufficient financial resources or infrastructure to adopt premium diagnostic solutions
• Overcoming these hurdles through improved affordability, strong technical support, and education on the clinical importance and benefits of immunoprotein diagnostics will be essential. Such initiatives can ensure sustained market growth by enabling healthcare providers to adopt these critical testing technologies more confidently and efficiently

Immunoprotein Diagnostic Testing Market Scope

The market is segmented on the basis of type, application, technology, and end user.

• By Type

On the basis of type, the immunoprotein diagnostic testing market is segmented into C-Reactive protein diagnostic test, complement system protein diagnostic test, pre-albumin diagnostic test, haptoglobin diagnostic test, immunoglobulin diagnostic test, free light chain diagnostic test, and others. The C-reactive protein diagnostic test segment dominated the market with the largest revenue share of 36.5% in 2024, driven by its extensive use in detecting inflammation and monitoring disease progression in both acute and chronic conditions. Its rapid results, reliability, and wide clinical application in hospital and laboratory settings have cemented its leading position. In addition, its compatibility with automated testing systems further supports high-volume testing needs, making it the preferred choice among clinicians.

The immunoglobulin diagnostic test segment is expected to witness the fastest CAGR of 19.8% from 2025 to 2032, fueled by rising demand for immunodeficiency testing and monitoring of autoimmune disorders. Increasing prevalence of conditions such as multiple myeloma, primary immunodeficiencies, and other antibody-related disorders is driving growth. The segment benefits from technological advancements in assay sensitivity and specificity, along with growing awareness among healthcare providers regarding early detection and accurate diagnosis.

• By Application

On the basis of application, the market is segmented into autoimmune testing, infectious disease testing, allergy testing, endocrine testing, oncology testing, toxicology testing, and others. The infectious disease testing segment held the largest market revenue share of 34.7% in 2024, supported by the increasing prevalence of viral and bacterial infections globally. Rising demand for rapid and accurate diagnostic tests, particularly in hospital laboratories and public health centers, contributes to its dominance. The growing need for early diagnosis, outbreak monitoring, and effective patient management reinforces its market leadership.

The oncology testing segment is projected to witness the fastest CAGR of 20.3% from 2025 to 2032, reflecting the growing global prevalence of various cancers and the increasing reliance on immunoprotein biomarkers for critical clinical applications. The rising adoption of these biomarkers for early detection enables healthcare providers to identify cancer at more treatable stages, significantly improving patient prognosis. In addition, immunoprotein diagnostics play a pivotal role in therapy monitoring, allowing clinicians to evaluate treatment efficacy and make timely adjustments to therapeutic regimens. Enhanced awareness of personalized medicine and the development of targeted therapies are further driving demand, as physicians and researchers prioritize highly accurate and specific diagnostic tools.

• By Technology

On the basis of technology, the market is segmented into radioimmunoassay, immunoturbidity assay, immunoprotein electrophoresis, enzyme-linked immunosorbent assay, and others. The enzyme-linked immunosorbent assay (ELISA) segment dominated with a revenue share of 38.9% in 2024, owing to its high sensitivity, specificity, and versatility in detecting a broad range of immunoproteins. ELISA’s adaptability across clinical, research, and diagnostic laboratory settings makes it a widely preferred method. Automated ELISA platforms also support high-throughput testing, further reinforcing its market position.

The immunoprotein electrophoresis segment is anticipated to achieve the fastest CAGR of 18.7% from 2025 to 2032, largely propelled by its critical role in detecting and quantifying abnormal protein patterns associated with a variety of conditions, including multiple myeloma, amyloidosis, and other plasma cell disorders. Its ability to provide precise and reliable diagnostic information makes it an indispensable tool in clinical settings, facilitating accurate disease identification and effective patient management. The increasing utilization of immunoprotein electrophoresis in clinical laboratories is further driving market expansion, as healthcare providers seek advanced methodologies to enhance diagnostic accuracy.

• By End User

On the basis of end user, the market is segmented into hospitals and clinics, diagnostic laboratories, and others. The hospitals and clinics segment accounted for the largest market revenue share of 41.2% in 2024, due to the high volume of routine and specialized immunoprotein diagnostic testing performed in these settings. Hospitals benefit from centralized testing facilities, integrated laboratory workflows, and access to automated diagnostic systems, which enhance accuracy and efficiency.

The diagnostic laboratories segment is projected to register the fastest CAGR of 19.5% from 2025 to 2032, driven by the growing trend of outsourcing immunoprotein testing to specialized laboratories, which allows healthcare providers to access high-quality, precise diagnostic services without significant capital investment. The rising prevalence of chronic diseases, such as autoimmune disorders, infectious diseases, and cancer, is creating increased demand for specialized and reliable immunoprotein assays, further propelling the adoption of laboratory-based testing.

Immunoprotein Diagnostic Testing Market Regional Analysis

• North America dominated the immunoprotein diagnostic testing market with the largest revenue share of 40.5% in 2024, supported by advanced healthcare infrastructure, high disposable incomes, and a strong presence of key industry players
• High healthcare expenditure and ongoing investments in precision diagnostics are further strengthening the market
• The adoption of automated testing platforms and the integration of advanced immunoprotein assays in routine clinical practice are driving demand, particularly in hospitals, specialty clinics, and diagnostic centers

U.S. Immunoprotein Diagnostic Testing Market Insight

The U.S. immunoprotein diagnostic testing market captured a dominant share within North America in 2024, driven by technological advancements in immunoassay platforms and growing adoption across hospitals and diagnostic laboratories. Increasing prevalence of chronic and lifestyle diseases is expanding the need for precise immunoprotein testing, including biomarkers for oncology, autoimmune, and infectious disease applications. Furthermore, ongoing government support for healthcare innovations, coupled with rising awareness among clinicians about early disease detection, is fueling robust market growth. Expansion of laboratory infrastructure and the adoption of high-throughput testing solutions further enhance market penetration.

Europe Immunoprotein Diagnostic Testing Market Insight

The Europe immunoprotein diagnostic testing market is projected to expand at a substantial CAGR during the forecast period, supported by well-established healthcare systems, regulatory frameworks, and growing awareness about early disease diagnosis. Countries such as Germany, the U.K., and France are witnessing rising adoption of advanced immunoprotein diagnostic assays for oncology, autoimmune, and infectious diseases. Investments in state-of-the-art laboratory infrastructure, coupled with the demand for standardized and high-accuracy testing methods, are driving market growth. In addition, healthcare initiatives promoting preventive care and the increasing focus on personalized medicine are encouraging the uptake of immunoprotein diagnostic solutions.

U.K. Immunoprotein Diagnostic Testing Market Insight

The U.K. immunoprotein diagnostic testing market is expected to grow at a notable CAGR during the forecast period, driven by increasing awareness about the clinical value of immunoprotein testing and rising prevalence of chronic diseases. Expansion of diagnostic laboratories and hospitals equipped with advanced immunoassay platforms is facilitating higher adoption rates. Rising government and private healthcare initiatives supporting early disease detection, as well as growing interest in personalized treatment strategies, are further strengthening market demand. The U.K.’s well-developed healthcare infrastructure and increasing investments in research are expected to continue stimulating market growth.

Germany Immunoprotein Diagnostic Testing Market Insight

The Germany immunoprotein diagnostic testing market is anticipated to witness significant growth throughout the forecast period, propelled by increasing adoption of advanced immunoassay platforms and high awareness regarding preventive healthcare. The country’s strong healthcare infrastructure, emphasis on technological innovations, and rising prevalence of chronic and infectious diseases are key factors driving the market. Integration of immunoprotein diagnostics into routine hospital and laboratory testing, along with growing demand for early detection and monitoring of autoimmune and oncological conditions, is further boosting market growth.

Asia-Pacific Immunoprotein Diagnostic Testing Market Insight

The Asia-Pacific immunoprotein diagnostic testing market is poised to register the fastest CAGR during the forecast period from 2025 to 2032. This rapid growth is fueled by increasing urbanization, expansion of healthcare infrastructure, rising disposable incomes, and growing awareness about immunoprotein diagnostics in countries such as China, India, and Japan. Investment in laboratory facilities, along with government initiatives to enhance diagnostic accessibility, is enabling wider adoption. In addition, the rising prevalence of chronic and infectious diseases is driving demand for precise and cost-effective immunoprotein testing solutions across hospitals, diagnostic centers, and specialty clinics.

Japan Immunoprotein Diagnostic Testing Market Insight

The Japan immunoprotein diagnostic testing market is gaining momentum due to high healthcare standards, rapid urbanization, and growing emphasis on early diagnosis and disease management. Increasing demand for advanced diagnostic solutions to support oncology, autoimmune, and infectious disease testing is propelling growth. Investments in modern laboratory infrastructure and adoption of sophisticated immunoprotein assays are further strengthening the market. In addition, the country’s aging population is likely to drive demand for immunoprotein testing in both clinical and outpatient settings.

China Immunoprotein Diagnostic Testing Market Insight

The China immunoprotein diagnostic testing market accounted for the largest market revenue share in the Asia-Pacific region in 2024, attributed to rising healthcare access, expanding middle-class population, and increasing government investment in diagnostic technologies. The growing prevalence of chronic and lifestyle diseases, coupled with heightened awareness of immunoprotein testing, is driving market demand. Expansion of hospital and laboratory networks, along with improved affordability of immunoprotein diagnostic solutions, is enabling wider adoption across the country. China’s role as a hub for medical technology innovation is also supporting the development and deployment of advanced immunoprotein testing platforms.

Immunoprotein Diagnostic Testing Market Share

The immunoprotein diagnostic testing industry is primarily led by well-established companies, including:

• Abbott (U.S.)
• Abcam Limited (U.K.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Danaher Corporation (U.S.)
• DiaSorin S.p.A. (Italy)
• Enzo Biochem Inc. (U.S.)
• QuidelOrtho Corporation. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• BIOMÉRIEUX (France)
• Adaltis S.r.l. (Italy)
• Agilent Technologies Inc. (U.S.)
• Enzo Biochem Inc. (India)
• Randox Laboratories Ltd (U.K.)
• SERVA Electrophoresis GmbH (Germany)
• Calbiotech (U.S.)
• Eurobio Scientific (France)
• Meridian Bioscience, Inc. (U.S.)
• A. Menarini Diagnostics S.r.l. (Italy)
• Lilly (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Siemens Healthineers AG (Germany)

Latest Developments in Global Immunoprotein Diagnostic Testing Market

• In May 2024, Bio-Techne reported higher-than-expected profits and revenues for the third quarter, driven by strong demand for its cell and gene therapy products as well as testing and diagnostic devices. The company's diagnostics and genomics unit saw a 16% rise in revenue to USD87.5 million
• In October 2024, Bio-Techne exceeded first-quarter profit expectations, driven by growth in its diagnostics and spatial biology segment. The diagnostics and spatial biology revenue increased by 14% to USD 83.2 million
• In June 2025, an extensive examination of the immunoprotein diagnostic testing market highlighted major players such as Abbott Laboratories, Abcam PLC, and Agilent Technologies. These companies are expected to experience substantial growth during the forecast period from 2025 to 2032

SKU-56900